Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Rapid regression of glioblastoma following carmustine wafer implantation: A case report.

Fukai J, Nishibayashi H, Uematsu Y, Kanemura Y, Fujita K, Nakao N.

Mol Clin Oncol. 2016 Jul;5(1):153-157. Epub 2016 May 10.

2.

Glioblastoma in the elderly: making sense of the evidence.

Mason M, Laperriere N, Wick W, Reardon DA, Malmstrom A, Hovey E, Weller M, Perry JR.

Neurooncol Pract. 2016 Jun;3(2):77-86. Epub 2015 Sep 1.

PMID:
27275387
3.

MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.

Lohkamp LN, Schinz M, Gehlhaar C, Guse K, Thomale UW, Vajkoczy P, Heppner FL, Koch A.

PLoS One. 2016 Jun 2;11(6):e0156422. doi: 10.1371/journal.pone.0156422. eCollection 2016.

4.

Accelerated hyperfractionation plus temozolomide in glioblastoma.

Kaul D, Florange J, Badakhshi H, Grün A, Ghadjar P, Exner S, Budach V.

Radiat Oncol. 2016 May 21;11(1):70. doi: 10.1186/s13014-016-0645-3.

5.

Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma.

Khosla D.

Ann Transl Med. 2016 Feb;4(3):54. doi: 10.3978/j.issn.2305-5839.2016.01.25. Review.

6.

Evolving Molecular Genetics of Glioblastoma.

Li QJ, Cai JQ, Liu CY.

Chin Med J (Engl). 2016 Feb 20;129(4):464-71. doi: 10.4103/0366-6999.176065.

7.

Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.

Mallick S, Gandhi AK, Rath GK.

Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):229-37. doi: 10.4103/0971-5851.171543. Review.

8.

Radiation de-intensification for patients with glioblastoma and poor prognostic features--how much do we really know?

Alexander BM.

Neuro Oncol. 2016 Feb;18(2):147-8. doi: 10.1093/neuonc/nov311. No abstract available.

PMID:
26803808
9.

Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.

Mendez JS, Govindan A, Leong J, Gao F, Huang J, Campian JL.

J Neurooncol. 2016 Apr;127(2):329-35. doi: 10.1007/s11060-015-2037-1. Epub 2016 Jan 4.

PMID:
26725885
10.

Has the survival of patients with glioblastoma changed over the years?

deSouza RM, Shaweis H, Han C, Sivasubramiam V, Brazil L, Beaney R, Sadler G, Al-Sarraj S, Hampton T, Logan J, Hurwitz V, Bhangoo R, Gullan R, Ashkan K.

Br J Cancer. 2016 Jan 19;114(2):146-50. doi: 10.1038/bjc.2015.421. Epub 2015 Dec 15.

PMID:
26671748
11.

Glioblastoma in the elderly: Therapeutic dilemmas.

Pereira AF, Carvalho BF, Vaz RM, Linhares PJ.

Surg Neurol Int. 2015 Nov 16;6(Suppl 23):S573-82. doi: 10.4103/2152-7806.169542. eCollection 2015.

12.

Advances in the treatment of newly diagnosed glioblastoma.

Theeler BJ, Gilbert MR.

BMC Med. 2015 Dec 8;13:293. doi: 10.1186/s12916-015-0536-8. Review.

13.
14.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.

J Natl Cancer Inst. 2015 Nov 27;108(5). pii: djv369. doi: 10.1093/jnci/djv369. Print 2016 May.

PMID:
26615020
15.

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.

Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, Li G, Li S, Wu C, Yao K, Li W, Yan W, Li J, You Y, Chen CC, Jiang T.

Oncotarget. 2015 Dec 1;6(38):40896-906. doi: 10.18632/oncotarget.5683.

16.

Current status and future directions of anti-angiogenic therapy for gliomas.

Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, Winkler F.

Neuro Oncol. 2016 Mar;18(3):315-28. doi: 10.1093/neuonc/nov180. Epub 2015 Oct 12. Review.

PMID:
26459812
17.

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Hegi ME, Stupp R.

Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15. No abstract available.

PMID:
26374690
18.

Drug and gene delivery across the blood-brain barrier with focused ultrasound.

Timbie KF, Mead BP, Price RJ.

J Control Release. 2015 Dec 10;219:61-75. doi: 10.1016/j.jconrel.2015.08.059. Epub 2015 Sep 8.

PMID:
26362698
19.

Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.

Rudà R, Bosa C, Magistrello M, Franchino F, Pellerino A, Fiano V, Trevisan M, Cassoni P, Soffietti R.

Neuro Oncol. 2016 Feb;18(2):261-8. doi: 10.1093/neuonc/nov167. Epub 2015 Aug 30.

PMID:
26323606
20.

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions.

Bienkowski M, Berghoff AS, Marosi C, Wöhrer A, Heinzl H, Hainfellner JA, Preusser M.

Clin Neuropathol. 2015 Sep-Oct;34(5):250-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk